Browse Penn-owned technologies available for licensing.
Dr. Ridky proposes a CAR-T cell based technology to selective killing of melanocytes. These CAR’s do not target uveal melanocytes. Killing of melanoma cells and melanocytes, with little to no killing of human fibroblasts using these engineered CAR T-cells was shown in vitro as well as in vivo in NSG mice. But melanocytes are dispensable.